financetom
Business
financetom
/
Business
/
UK regulator refers Getty-Shutterstock merger for an in-depth investigation
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UK regulator refers Getty-Shutterstock merger for an in-depth investigation
Nov 3, 2025 6:00 AM

(Reuters) -Britain's competition watchdog said on Monday it will launch an investigation into the proposed merger between U.S.-based Getty Images ( GETY ) and rival Shutterstock ( SSTK ) after remedies offered by the companies failed to address its concerns.

Getty and Shutterstock ( SSTK ) offered a "complex package of remedies" late in the Phase 1 investigation, but the regulator said these did not fully address concerns the deal could lead to higher prices and lower quality editorial and stock imagery.

Getty shares fell over 7% while Shutterstock ( SSTK ) dropped 2% in U.S. premarket trading.

The Competition and Markets Authority (CMA) said it had heard concerns from businesses, trade associations and industry stakeholders including the News Media Association over the merger of the world's largest photo licensing platforms.

Getty Images ( GETY ) said in a statement it had offered comprehensive remedies to avoid a Phase 2 review and was disappointed by the CMA's decision, while both companies said they remain committed to the merger and will continue engaging with the regulator.

The CMA said in late October the merger could substantially harm competition in editorial and stock photography markets and reduce service quality for UK media organisations and creative businesses.

Getty and Shutterstock ( SSTK ) struck a $3.7 billion deal in January to form a stock-image powerhouse at a time when generative AI tools are increasingly disrupting the industry.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,034,085, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,034,085, According to a Recent SEC Filing
Oct 3, 2025
05:18 PM EDT, 10/03/2025 (MT Newswires) -- Yvonne Greenstreet, Director, Chief Executive Officer, on October 01, 2025, sold 8,924 shares in Alnylam Pharmaceuticals ( ALNY ) for $4,034,085. Following the Form 4 filing with the SEC, Greenstreet has control over a total of 65,816 common shares of the company, with 65,409 shares held directly and 407 controlled indirectly. SEC Filing:...
Arcutis Biotherapeutics Insider Sold Shares Worth $884,649, According to a Recent SEC Filing
Arcutis Biotherapeutics Insider Sold Shares Worth $884,649, According to a Recent SEC Filing
Oct 3, 2025
05:15 PM EDT, 10/03/2025 (MT Newswires) -- Todd Watanabe, Director, President and Chief Executive Officer, on October 01, 2025, sold 45,000 shares in Arcutis Biotherapeutics ( ARQT ) for $884,649. Following the Form 4 filing with the SEC, Watanabe has control over a total of 1,079,574 common shares of the company, with 846,440 shares held directly and 233,134 controlled indirectly....
AbbVie trims annual profit forecast after expected $2.7 billion R&D hit
AbbVie trims annual profit forecast after expected $2.7 billion R&D hit
Oct 3, 2025
(Reuters) -Drugmaker AbbVie said on Friday it has lowered its annual profit forecast, after a flagging an expected $2.7 billion charge related to in-process research and development (IPR&D) expenses in the third quarter. Shares of the North Chicago-based company were down nearly 1% at $232.0 in extended trade. AbbVie ( ABBV ) said in a regulatory filing that such expenses...
AbbVie trims annual profit forecast after expected $2.7 billion R&D hit
AbbVie trims annual profit forecast after expected $2.7 billion R&D hit
Oct 3, 2025
Oct 3 (Reuters) - Drugmaker AbbVie said on Friday it has lowered its annual profit forecast, after a flagging an expected $2.7 billion charge related to in-process research and development (IPR&D) expenses in the third quarter. Shares of the North Chicago-based company were down nearly 1% at $232.0 in extended trade. AbbVie ( ABBV ) said in a regulatory filing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved